AGI-5198 is a reversible competitive inhibitor selectively targeting the IDH1 R132H mutant enzyme, which resulted in reduced D-2-HG level, suppressed cellular proliferation, and enhanced cell differentiation in human glioma cells and mouse models [117,135]. The gene discussed is IDH1; the disease is glioma.